<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626285</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00010804</org_study_id>
    <secondary_id>NCI-2018-00556</secondary_id>
    <secondary_id>IRB00010804</secondary_id>
    <nct_id>NCT03626285</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders</brief_title>
  <official_title>Institutional Protocol of Bone Marrow Transplantation Using CD34-Selected Peripheral Blood Stem Cells From Related Haploidentical or Unrelated Donors for Treatment of Malignant and Nonmalignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      This expanded access protocol studies bone marrow transplantation using CD34-selected stem&#xD;
      cells from related or unrelated donors in treating participants with cancer or other&#xD;
      disorders. Stem cells collected from the donor will be processed using a new device called&#xD;
      CliniMACS CD34 Reagent System which marks the blood cells collected from the donor with a&#xD;
      special protein called &quot;antibody&quot; that tags only the donor stem cells, sorting out other&#xD;
      cells of the blood and immune system. This is done to remove, at least partially, some of the&#xD;
      T cells. T cells are the cells in the blood that work as scavengers of the immune system&#xD;
      deciding what belongs and what does not. These cells can sometimes cause rejection of the&#xD;
      donor graft or a condition called graft-versus host disease (GVHD), where the donor cells can&#xD;
      attack the body of the recipient. A bone marrow transplantation using CD34-selected stem&#xD;
      cells may reduce the risk of these unwanted side effects of transplant as much as possible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To provide a source of CD34-selected stem cells for patients with malignant and&#xD;
      nonmalignant disorders undergoing bone marrow transplantation from haploidentical (human&#xD;
      leukocyte antigen [HLA]-mismatched) related donors or HLA-compatible unrelated donors&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Monitoring the safety of the CD34-selected stem cells for the recipient, as measured by&#xD;
      adverse events related to stem cell infusion, incidence of engraftment of neutrophils and&#xD;
      platelets, incidence of acute and chronic GVHD, and one year overall survival, disease-free&#xD;
      survival, and primary disease recurrence.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Donor stem cells undergo CD34 selection ex vivo using the CliniMACS CD34 Reagent System using&#xD;
      standard operating procedures (SOPs) from the manufacturer. Recipients undergo standard of&#xD;
      care preparative regimen, bone marrow transplantation with CD34-selected peripheral blood&#xD;
      stem cells via infusion over 1 to 2 hours on day 0, and then receive standard of care GVHD&#xD;
      prophylaxis.&#xD;
&#xD;
      After completion of study treatment, recipients are followed up at least once weekly while&#xD;
      inpatient until transplant day 100, every 1-3 months for the first year and yearly&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Benign Neoplasm</condition>
  <condition>Bone Marrow Transplantation Recipient</condition>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <condition>Malignant Neoplasm</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplantation</intervention_name>
    <description>Undergo BMT</description>
    <other_name>BMT</other_name>
    <other_name>Bone Marrow Grafting</other_name>
    <other_name>Bone marrow transplant</other_name>
    <other_name>Marrow Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS CD34 Reagent System</intervention_name>
    <description>CD34 selection ex vivo</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Receive CD34-selected peripheral blood stem cells from related or unrelated donors</description>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with malignant or nonmalignant diseases that can benefit from alternative&#xD;
             stem cell transplantation according to institutional standard practice guidelines&#xD;
&#xD;
          -  Patients lacking a healthy human leukocyte antigen (HLA)-identical related donor and&#xD;
             having one of the following alternative donor sources:&#xD;
&#xD;
               -  HLA-haploidentical related (HLA antigen genotypic match &gt;= 4/8 and &lt;= 7/8) or&#xD;
&#xD;
               -  Unrelated donor that is HLA matched at &gt;= 7/8 HLA antigen loci&#xD;
&#xD;
          -  The selected donor must also be:&#xD;
&#xD;
               -  Able to receive granulocyte colony-stimulating factor (G-CSF, filgrastim) and&#xD;
                  undergo apheresis either through placement of peripheral or temporary central&#xD;
                  venous catheter, based on institutional guidelines for peripheral blood stem cell&#xD;
                  collection&#xD;
&#xD;
               -  Meet all institutional standard criteria for clearance for peripheral stem cell&#xD;
                  collection&#xD;
&#xD;
          -  Recipients must meet institutional treatment standards based on pre-transplant&#xD;
             evaluations including:&#xD;
&#xD;
               -  Adequate major organ functions&#xD;
&#xD;
               -  Free of major systemic infections&#xD;
&#xD;
               -  Not pregnant, if female of childbearing age (post-pubertal)&#xD;
&#xD;
          -  Recipient (if &gt;= 18 years) or their parent/legal guardian (if &lt; 18 years) must be able&#xD;
             to sign the informed consent form for the treatment plan; assent will be obtained from&#xD;
             recipients 7-17 years of age, in accordance to our institutional guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not meeting clearance criteria for bone marrow transplantation (BMT) based on&#xD;
             standard institutional guidelines&#xD;
&#xD;
          -  Presence of anti-HLA antibodies against donor antigens in a recipient or anti-HLA&#xD;
             antibodies against recipient antigens in a donor&#xD;
&#xD;
          -  Known allergy to murine (mouse) protein or iron-dextran&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eneida Nemecek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eneida Nemecek, MD</last_name>
    <phone>503-494-0829</phone>
    <email>nemeceke@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Eneida R. Nemecek</last_name>
      <phone>503-494-0829</phone>
      <email>nemeceke@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Eneida R. Nemecek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Eneida Nemecek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

